|
| 唑来膦酸治疗COPD患者骨质疏松症的疗效及对肺功能影响的分析 |
| The efficacy of zoledronic acid on osteoporosis and pulmonary function in COPD patients |
| |
| DOI：10.3969/j.issn.1006.7108.2019.03.011 |
| 中文关键词: 唑来膦酸 慢性阻塞性肺疾病(COPD) 骨质疏松 肺功能 |
| 英文关键词:zoledronic acid osteoporosis COPD pulmonary function |
| 基金项目: |
|
| 摘要点击次数: 1301 |
| 全文下载次数: 467 |
| 中文摘要: |
| 目的 研究COPD患者骨质疏松症经唑来膦酸治疗的疗效及对肺功能影响。方法 COPD合并骨质疏松患者52例，给予唑来膦酸及基础药物治疗，疗程1年，测量治疗前后腰椎、髋部骨密度( BMD) 、肺功能及血清中血钙、血磷、骨特异性碱性膦酸酶( BALP)，血清骨钙素(BGP)和晨尿游离脱氧吡啶啉排泄率(Dpd／Cr)、VAS及活动能力评分。结果 治疗1年后疼痛症状改善，FEV1、FEV1％有显著提高，腰椎、股骨颈BMD升高，差异有统计学意义。治疗前FEV1、治疗后FEVl变化值△FEV1与腰椎骨密度变化值正相关。治疗后BGP值升高，ALP、Dpd／Cr值均下降，而血磷、血钙均无变化。结论 唑来膦酸可以增加骨密度，改善骨代谢，同时改善通气功能，可以应用在COPD骨质疏松症的治疗。 |
| 英文摘要: |
| Objective To evaluate the efficacy of zoledronic acid on osteoporosis in COPD patients and its influence in the pulmonary function. Methods Fifty-two COPD patients with osteoporosis were treated with zoledronic acid for 1 year. Bone mineral density (BMD) of the lumbar spine and the hip, pulmonary function, serum levels of Ca, P, BGP, BALP, Dpd/Cr, and VAS score were determined before and after the treatment. Results After 1-year treatment, the pain symptom relieved, FEV1 and FEV1 % increased significantly, and BMD of lumbar vertebrae and femoral neck increased. △FEV1, the change value of FEV1 and FEVl before and after the treatment, was positively correlated with BMD of the lumbar vertebrae. BGP increased significantly, ALP and Dpd/Cr decreased significantly after the treatment, and the serum levels of Ca and P had no change. Conclusion Zoledronic acid improves bone metabolism and BMD, and improves pulmonary function. It can be used in the treatment of osteoporosis in COPD patients. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|